1. Introduction {#sec1-ijms-20-03304}
===============

Sphingolipid metabolism starts in the endoplasmic reticulum (ER) with the condensation of serine and palmitic acid, producing 3-keto-dihydrosphingosine (also named 3-keto-sphinganine), and it continues through successive enzymatic reactions leading to the synthesis of ceramide \[[@B1-ijms-20-03304]\] ([Figure 1](#ijms-20-03304-f001){ref-type="fig"}). Ceramide plays several roles in cell homeostasis, itself acting as a regulator or through the generation of other bioactive lipids such as ceramide-1-phosphate and sphingosine-1-phosphate (S1P) \[[@B2-ijms-20-03304]\]. Nevertheless, a large amount is used as the backbone for the biosynthesis of sphingomyelin (SM) and glycosphingolipids (GSLs) ([Figure 2](#ijms-20-03304-f002){ref-type="fig"}). In particular, ceramide is acted upon by UGT8, galactosylceramide (GalCer) synthase (see [Table 1](#ijms-20-03304-t001){ref-type="table"}, [Table 2](#ijms-20-03304-t002){ref-type="table"} and [Table 3](#ijms-20-03304-t003){ref-type="table"} for enzyme symbols) in the ER \[[@B1-ijms-20-03304]\], and SGMS, SM synthase \[[@B3-ijms-20-03304]\] or UGCG, glucosylceramide (GlcCer) synthase \[[@B4-ijms-20-03304]\] in the Golgi apparatus. GlcCer may undergo many different further glycosylations, giving rise to a plethora of GSLs, depending on the specific glycosyltransferase machinery present in the various cell types. These include gangliosides, globosides, and other neutral compounds ([Figure 2](#ijms-20-03304-f002){ref-type="fig"}). Ceramide, SM, and GSLs flow through the Golgi to the plasma membrane or other organelles (such as mitochondria in the case of ceramide) via vesicular-mediated \[[@B5-ijms-20-03304]\] or protein-mediated traffic \[[@B6-ijms-20-03304]\]. The plasma membrane is considered the main destination of such compounds, which may also be delivered outside the cell in the form of microvesicles \[[@B7-ijms-20-03304]\] or channeled along the endocytic pathways toward phagosomes and lysosomes. In the lysosomes, complex sphingolipids are stepwise degraded to fatty acids and sphingosine ([Figure 1](#ijms-20-03304-f001){ref-type="fig"} and [Figure 2](#ijms-20-03304-f002){ref-type="fig"}). Sphingosine reaches the ER, where it enters the Cer--S1P signaling pathway. S1P can be also degraded to phosphoethanolamine and 2-hexadecenal \[[@B1-ijms-20-03304]\] ([Figure 1](#ijms-20-03304-f001){ref-type="fig"}). Defects of specific lysosomal hydrolases ([Table 1](#ijms-20-03304-t001){ref-type="table"}) involved in this process have been known for several years and constitute the main group of lysosomal storage disorders due to inborn errors of metabolism \[[@B8-ijms-20-03304]\]. These include the gangliosidoses, Niemann--Pick disease, Fabry disease, Krabbe disease, Gaucher disease, and Farber disease. More recently, defects of several enzymes responsible for the biosynthetic steps ([Table 2](#ijms-20-03304-t002){ref-type="table"} and [Table 3](#ijms-20-03304-t003){ref-type="table"}) were found to be associated with human diseases: these include variants of serine palmitoyl transferases (SPTLC) \[[@B9-ijms-20-03304],[@B10-ijms-20-03304]\], 3-keto-dihydro-sphingosine reductase (KDSR) \[[@B11-ijms-20-03304],[@B12-ijms-20-03304],[@B13-ijms-20-03304]\], dihydro-ceramide synthases (CERS) \[[@B14-ijms-20-03304],[@B15-ijms-20-03304],[@B16-ijms-20-03304],[@B17-ijms-20-03304],[@B18-ijms-20-03304]\], dihydroceramide desaturase (DEGS) \[[@B19-ijms-20-03304],[@B20-ijms-20-03304],[@B21-ijms-20-03304]\], sphingomyelin synthases (SGMS) \[[@B22-ijms-20-03304],[@B23-ijms-20-03304]\], GlcCer synthase (UGCG) \[[@B24-ijms-20-03304]\], GM3 synthase (ST3GAL5), GM2/GD2/GA2 synthase (B4GALNT1), and CMP-Sial: GlcNAcβ1,3(4) sialyltransferase (ST3GAL3) \[[@B25-ijms-20-03304]\]. The latter four enzymes are glycosyltransferases and, thus, the related diseases belong to the wide family of the congenital disorders of glycosylation (CDG) \[[@B26-ijms-20-03304]\]. It is worth noting that some enzymes of sphingolipid metabolism exist in different isoforms representing different gene products, sometimes with different subcellular localization, as in the case of ceramidases, ceramide synthases, sphingomyelinases, and SM synthases ([Table 1](#ijms-20-03304-t001){ref-type="table"}, [Table 2](#ijms-20-03304-t002){ref-type="table"} and [Table 3](#ijms-20-03304-t003){ref-type="table"}). It is not surprising that disorders involving different isoforms may produce very different clinical phenotypes. Variants of CERS1 and -2 result in a myoclonus epilepsy \[[@B14-ijms-20-03304],[@B15-ijms-20-03304],[@B17-ijms-20-03304]\], while CERS3 variants determine a form of ichthyosis \[[@B16-ijms-20-03304]\]. Glucocerebrosidase (GBA) variants are responsible for Gaucher disease (GD) \[[@B27-ijms-20-03304]\], while GBA2 variants result in hereditary spastic paraplegia 46 (HSP46) \[[@B28-ijms-20-03304]\]. Acid ceramidase ASAH1 deficiency is the cause of Farber disease \[[@B29-ijms-20-03304]\], while alkaline ceramidase (ACER3) variants are responsible for progressive leucodystrophy \[[@B30-ijms-20-03304]\]. Many of such disorders result in extremely heterogeneous clinical syndromes, in terms of both symptoms and severity, and some give rise to clinical features overlapping those of disorders involving totally unrelated genes \[[@B31-ijms-20-03304]\]. GD is the most relevant example of the former. The clinical presentation ranges from a mild visceral impairment detectable in adulthood to a severe neurologic impairment that is lethal by early childhood, without a clear relationship with the underlying mutation or the amounts of residual enzyme activity \[[@B27-ijms-20-03304],[@B32-ijms-20-03304],[@B33-ijms-20-03304]\]. On the other hand, B4GALNT1-CDG is one of about 70 known genetic defects determining an inherited spastic paraplegia \[[@B34-ijms-20-03304]\], and ST3GAL3-CDG is reported as one of the many conditions causing West syndrome, potentially evolving to Lennox--Gestaut syndrome \[[@B35-ijms-20-03304]\]. Many such disorders are typically transmitted in an autosomal recessive manner (see [Table 1](#ijms-20-03304-t001){ref-type="table"}, [Table 2](#ijms-20-03304-t002){ref-type="table"} and [Table 3](#ijms-20-03304-t003){ref-type="table"}). However, emerging data show that heterozygous carriers of glucocerebrosidase GBA \[[@B33-ijms-20-03304]\], sphingomyelinase SMPD1 \[[@B36-ijms-20-03304]\], galactocerebrosidase (GALC) \[[@B37-ijms-20-03304]\], and α-galactosidase (GLA) \[[@B38-ijms-20-03304]\] variants are as much at risk for neurodegenerative diseases such as synucleopathies and multiple sclerosis as those with recessive homozygotes.

The purpose of this review is to evaluate recent data concerning disorders of sphingolipid metabolism where the pathogenic role played by the loss of function of enzymes appears unable to explain the whole picture, while other mechanisms seem to cooperate with the clinical phenotype. Among them, the emerging candidates include the impairment of vesicle traffic in the context of autophagy/lysosome function and altered trafficking and metabolism of the variant proteins. In this regard, the data on GD as the main risk factor for Parkinson's disease (PD) suggest that the GD/PD connection may represent a pathogenic paradigm able to shed light on other disorders of sphingolipid metabolism. In particular, we focus on those affecting ganglioside biosynthesis as the disorders where such aspects could be relevant. This is interesting not only to better understand sphingolipid biology and the disease pathogenesis, but to address novel potential therapeutic strategies.

2. GBA Variants, GD, PD, and How They Interplay {#sec2-ijms-20-03304}
===============================================

GD is a lysosomal storage disorder caused by recessive mutations in the *GBA* gene, coding the β-galactosidase responsible for the degradation of GlcCer to glucose and ceramide \[[@B39-ijms-20-03304]\]. Reduced GBA activity leads to the accumulation of GlcCer and/or its immediate by-product glucosylsphingosine (GlcSph), formed by the action of acid ceramidase on GlcCer ([Figure 3](#ijms-20-03304-f003){ref-type="fig"}). GBA is synthesized in the ER as a 536- or 516-amino-acid protein, containing a short signal peptide of 19 or 39 amino acids at the N-terminus that is trimmed soon after translation \[[@B40-ijms-20-03304]\]. The residual 497 amino acid peptide is then glycosylated \[[@B41-ijms-20-03304]\] and recognized by the SCARB2 (scavenger receptor class B member 2) system \[[@B42-ijms-20-03304]\]. The GBA/SCARB2 complex \[[@B43-ijms-20-03304]\] experiences traffic through the Golgi apparatus and endocytic vesicles and then reaches the lysosomes, which are the sites of action. In the lysosomes, GBA activity is also controlled by the activator protein saponisin C. Another glucocerebrosidase is coded by the human genome, GBA2, which has a microsomal localization and is not involved in GD but instead is responsible for a form of HSP, reported as HSP46 \[[@B28-ijms-20-03304],[@B44-ijms-20-03304]\] ([Table 1](#ijms-20-03304-t001){ref-type="table"}). From a clinical point of view, patients suffering GD present two main distinct syndromes \[[@B8-ijms-20-03304],[@B27-ijms-20-03304]\]. Type 1 GD is characterized by the involvement of several visceral organs without that of the central nervous system, while types 2 and 3 present serious neurologic symptoms and are defined as neuronopathic GD. Symptoms of type 1 disease appear in adulthood and classically include anemia, hepatosplenomegaly, bone pain, and other inflammatory signs. The inflammatory effect of GlcCer accumulation was recently proposed to be the consequence of complement C5a activation \[[@B45-ijms-20-03304]\]. However, more recent reports identified patients with type 1 GD developing peripheral polyneuropathy at an older age \[[@B33-ijms-20-03304]\]. Moreover, a subset of patients was recently reported to present mild but distinctive intellectual impairment, suggesting an involvement of the central nervous system \[[@B46-ijms-20-03304],[@B47-ijms-20-03304]\]. Conversely, neuronopathic disease is much more severe: early onset of neurologic symptoms includes supranuclear gaze palsy, cognitive impairment (frequently, features of oppositional defiant disorder), seizures, various muscular problems, and even sudden death. Rapid progression of the disease with death in early childhood is characteristic of type 2 disease, while in type 3 the progression is slower. Type 2 and 3 diseases are also suggested to be the more evident forms of a spectrum disease \[[@B33-ijms-20-03304]\]. About 300 different mutations have been reported to affect the *GBA* gene. Some of them, such as L444P and N370S, are more frequent and account for several cases. There is a wide variety of mutation frequency between ethnicities. For instance, up to 1 in every 15 persons is considered a carrier of a *GBA* mutation in the Ashkenazi Jewish population, versus 1 in every 100 for others \[[@B27-ijms-20-03304],[@B48-ijms-20-03304]\]. Despite several attempts to find a correlation between individual mutations and the clinical syndrome, none have been firmly established so far, and patients affected by the same mutation present a large variability of symptoms \[[@B27-ijms-20-03304],[@B32-ijms-20-03304]\]. Data of the residual enzyme activity and its potential role as a predictor of disease severity are also contradictory \[[@B33-ijms-20-03304],[@B49-ijms-20-03304]\]. Both the common L444P and N370S variants are associated with a similar strong reduction in enzyme activity, about 80--90% compared with the wild type enzyme \[[@B50-ijms-20-03304]\]. Conversely, the N370S variant is more frequently associated with the type 1 disease and a mild or very mild phenotype, while the L444P variant is associated with type 3 disease and a severe neuronopathic phenotype in general. Some reports indicate that GBA variants are instable or misfolded proteins, which do not undergo normal intracellular traffic, irrespective of the amount of catalytic activity maintained \[[@B39-ijms-20-03304],[@B50-ijms-20-03304]\], suggesting a role for proteostasis in GD. A very intriguing issue in this field is the epidemiological evidence, established about 10 years ago, that *GBA* mutations are the major genetic risk factors for the development of PD in elderly people \[[@B51-ijms-20-03304]\]. Such a risk is associated not only with GD but with the carrier status of heterozygous *GBA* variants, as proven in the family members of GD patients. The molecular mechanism linking GBA mutations to PD appears complex. Experimental evidence indicates that reduced GBA activity and concurrent accumulation of GlcCer takes places in normal aging of the mouse brain \[[@B52-ijms-20-03304]\]. In humans, reduced expression and activity of GBA was found in the substantia nigra of the post-mortem brains of patients suffering from PD, both sporadic and associated with GBA mutations \[[@B53-ijms-20-03304]\]. Pathologically, the hallmark of PD is the presence of Lewy bodies in affected cells, consisting of the accumulation of α-synuclein aggregates in the cells. The derangement of α-synuclein metabolism in PD is suspected to be the consequence of impaired autophagy and lysosome clearance \[[@B50-ijms-20-03304],[@B54-ijms-20-03304]\]. The interaction between GBA variants, with or without loss of GBA activity, and α-synuclein accumulation has been intensively studied in neuronal cultures and in animal models. Deposition of α-synuclein aggregates impairs vesicle trafficking \[[@B55-ijms-20-03304]\], which disrupts traffic of GBA and other hydrolases to the lysosomes, favoring further α-synuclein accumulation and self-maintenance of the pathogenic process \[[@B54-ijms-20-03304]\]. Accordingly, double transgenic mice heterozygous for a null GBA allele and expressing human α-synuclein showed a relevant disruption of dopaminergic neurons associated with the accumulation of GlcSph but not GlcCer \[[@B56-ijms-20-03304]\]. Comparable results were found by analyzing post-mortem brains of patients suffering sporadic PD or dementia with Lewy bodies, where the levels of α-synuclein were inversely correlated with those of the GBA protein and directly with those of GlcSph \[[@B57-ijms-20-03304]\]. On this basis, it was hypothesized that parallel reduction of GlcCer synthase activity, with concurrent lowering of the GSL levels and, in turn, the GlcCer load into the lysosomes, may prevent such derangement. Studies on GlcCer synthase inhibitors able to pass the blood--brain barrier are in progress as novel therapeutic approaches \[[@B58-ijms-20-03304]\]. In a cellular model of GBA deficiency, obtained by CRISP/Cas9 genome editing of HEK-293 cells, decreased ceramide levels were found to be associated with impaired secretory autophagy and intracellular α-synuclein accumulation \[[@B59-ijms-20-03304]\], which is prevented by exogenous ceramide supplement or acid ceramidase inhibition. These results point out that the relative loss of GBA activity and consequent accumulation of GlcCer or its by-product GlcSph, or ceramide depletion, are pathogenic, impairing lysosomal function and autophagy \[[@B60-ijms-20-03304]\] and, in turn, triggering the development of PD. Moreover, GBA deficiency may promote the spread of protein aggregates through extracellular vesicles \[[@B61-ijms-20-03304]\]. On the other hand, other data suggests that GBA activity and GlcCer/GlcSph/ceramide levels are not necessary to determine the increased risk of developing PD. Carriers of the E326K GBA variant, which maintain substantial enzymatic activity, present increased risk of developing PD, although such mutation does not determine GD in the homozygotes \[[@B62-ijms-20-03304]\]. Impaired autophagy due to GBA mutations was suggested to occur and to affect the clearance of damaged mitochondria as a consequence of altered proteostasis \[[@B50-ijms-20-03304],[@B63-ijms-20-03304]\]. In mouse and cellular models carrying the L444P GBA variant, the loss of lysosomal enzyme activity blocks the degradation of autophagic cargos, whereas the variant GBA protein impairs autophagy induction and the priming of damaged mitochondria, indicating a gain of toxic function for the mutant protein. This effect may be attributed to the ER retention of the variant GBA protein, resulting in an unfolded protein response \[[@B64-ijms-20-03304]\]. In a mouse model, overexpression in the striatum of the N370S GBA variant affects α-synuclein and, in particular, its secretion through exosomes, while the simple inhibition of enzyme activity by conditurol-β-epoxide does not \[[@B65-ijms-20-03304]\].

Enzyme replacement and substrate reduction therapies are currently approved and used in clinical practice for the treatment of GD patients suffering visceral symptoms of the disease \[[@B66-ijms-20-03304]\]. They are ineffective in neuronopathic GD because they are unable to cross the blood--brain barrier. In light of the emerging complexity of GD pathogenesis, the above-mentioned mechanisms of disease also provide new potential targets of therapeutic approaches \[[@B66-ijms-20-03304],[@B67-ijms-20-03304]\]. In particular, heterogeneity in the clinical outcome between patients harboring the same genotype introduced the concept of genetic modifiers of the disease. They are defined as genes able to alter the clinical phenotype of a disease, modifying the penetrance, expressivity, dominance, or pleiotropy of the causative defect. Several have been identified for GD, some acting directly on the GBA pathway (GBA2, SCARB2, UGCG), and others regulating lysosomal function (TFEB, transcription factor EB) or downstream pathways \[[@B68-ijms-20-03304]\]. Small molecules able to cross the blood--brain barrier are able to increase TFEB activity, inhibit UGCG \[[@B58-ijms-20-03304]\], or restore autophagy \[[@B69-ijms-20-03304]\], representing promising examples of such novel drugs.

3. Other Diseases of Sphingolipid Metabolism Determining or Predisposing Individuals to Neurodegenerative Disorders {#sec3-ijms-20-03304}
===================================================================================================================

The growing and converging evidence supporting lysosome involvement in PD and the relevance of GBA variants as the main genetic risk factors for developing the disease have prompted several researchers to study potential connections between other lysosomal diseases and neurodegenerative disorders (data are summarized in [Table 1](#ijms-20-03304-t001){ref-type="table"}). The first association was proposed between sphingomyelinase SMPD1 variants, causing Niemann--Pick disease types A and B and PD \[[@B70-ijms-20-03304]\], and received further confirmations suggesting that reduced sphingomyelinase activity led to α-synuclein accumulation \[[@B71-ijms-20-03304]\]. Niemann--Pick disease type C is clinically similar to Niemann-Pick disease type A, but is determined by mutations of a different gene (*NPDC1*, neural proliferation differentiation and control protein 1), coding a protein regulating endocytic transport in late endosomes and lysosomes. Interestingly, inhibition of GBA2 improves lysosomal function in fibroblasts from Niemann-Pick disease type C patients \[[@B72-ijms-20-03304]\]. Thus, the question rose as to whether mutations of other genes responsible for known lysosomal storage diseases predispose patients to PD. Analysis of a large whole exome sequencing dataset available for PD \[[@B73-ijms-20-03304]\] suggested the association of the disease with three proteins responsible for lysosomal diseases in addition to GBA and SMPD1. They include ASAH1 (acid ceramidase, causing Farber disease), CLN10 (cathepsin-D, a lysosomal aspartyl proteinase causing neuronal ceroid lipofuscinosis), and SLC17A5 (sialin, causing Salla disease). The latter is involved in the transport of the sialic acid residues released by the action of sialidases on gangliosides and glycoproteins out of lysosomes \[[@B74-ijms-20-03304]\]. Of note, Farber disease is a typical spectrum disease where patients carrying the same mutation present very different clinical features (reviewed in \[[@B29-ijms-20-03304]\]) ([Table 1](#ijms-20-03304-t001){ref-type="table"}). Neuronal ceroid lipofuscinosis is a neurodegenerative disorder determined by the mutations of at least 13 different genes, all somewhat involved in autophagy \[[@B75-ijms-20-03304]\]. Recent studies on α-galactosidase A (GLA) deficiency, causing Fabry disease, an X-linked disorder causing systemic symptoms, have suggested a possible association between GLA mutations and PD or multiple sclerosis \[[@B38-ijms-20-03304],[@B76-ijms-20-03304]\]. Moreover, GLA activity was reported to be lower in PD cases compared to controls \[[@B77-ijms-20-03304]\]. Similarly, galactocerebrosidase (GALC) mutations, causing Krabbe disease, are studied as potentially being related to neurodegeneration/multiple sclerosis and synucleopathies \[[@B78-ijms-20-03304],[@B79-ijms-20-03304],[@B80-ijms-20-03304]\]. In this regard, lysosphigolipids ([Figure 3](#ijms-20-03304-f003){ref-type="fig"}) formed in the disease, and even in GD, Fabry disease, Niemann-Pick disease, and GM1 gangliosidosis ([Table 1](#ijms-20-03304-t001){ref-type="table"}), were reported to affect endolysosomal transport and pH, leading to the possible formation of α-synuclein aggregates \[[@B81-ijms-20-03304],[@B82-ijms-20-03304]\]. Signs of Parkinsonism are now considered to be detectable in various inherited metabolic disorders in addition to GD and Niemann Pick disease \[[@B83-ijms-20-03304]\]. Recent studies highlight the potential link between PD and sphingolipids, particularly gangliosides. They were found to promote α-synuclein aggregation in vitro \[[@B84-ijms-20-03304]\]. In cellular models, accumulation of gangliosides due to reduced activity of GBA variants prevented the formation of stable α-synuclein tetramers, and pharmacologic (miglustat) inhibition of GSL biosynthesis restored α-synuclein stabilization \[[@B85-ijms-20-03304]\]. Reduced expression of galactosyltransferase B3GALT4 and sialyltransferase ST3GAL2, as detected by in situ hybridization, was found to occur specifically in neuromelanin producing neurons of the brains of PD patients \[[@B86-ijms-20-03304]\]. Plasma levels of GM3 were found to be increased in PD patients \[[@B87-ijms-20-03304]\].

It is also interesting to consider the data now available from inherited diseases of sphingolipid metabolism very recently reported ([Table 2](#ijms-20-03304-t002){ref-type="table"} and [Table 3](#ijms-20-03304-t003){ref-type="table"}). In the defects of serine palmitoyl transferases *SPTLC1-2* and dihydroceramide desaturase *DEGS1*, causing forms of hereditary sensory neuropathy type 1 and hypomyelinating leukodystrophy, respectively, the presence of potentially toxic compounds is suspected to be involved in the disease pathogenesis. In particular, deoxysphingolipids formed by SPTLC1-2 variants were found to exert mitochondrial toxicity \[[@B10-ijms-20-03304]\], and increased amounts of reactive oxygen species (ROS) were detected in fibroblasts from patients carrying DEGS1 variants. Interestingly, pharmacological inhibition of CERS prevents ROS accumulation \[[@B21-ijms-20-03304]\].

Heterozygous variants of sphingomyelin synthase SGMS2, an enzyme coding a plasma membrane form of sphingomyelin synthase, were found associated with the clinical picture of Osteoporosis with Skeletal Dysplasia. Interestingly, the main clinical signs are restricted to the bones, but a spectrum of mild or very mild neurologic symptoms were detected. Disease severity appeared dependent on mislocalization of enzyme variants more than on levels of residual activity \[[@B23-ijms-20-03304]\].

Together, these data suggest that sphingolipid metabolism interacts with cellular homeostasis through several mechanisms that can be affected by enzyme mutations, as recapitulated by the ability of GBA variants to determine a spectrum disease, including neurodegenerative disorders such as PD.

4. Specific Diseases of Ganglioside Biosynthesis Determining Neurodegenerative Disorders {#sec4-ijms-20-03304}
========================================================================================

4.1. GM2 Synthase Deficiency (B4GALNT1-CDG), HSP26, and Other HSPs {#sec4dot1-ijms-20-03304}
------------------------------------------------------------------

B4GALNT1 is the enzyme necessary to extend all ganglio-series gangliosides \[[@B88-ijms-20-03304],[@B89-ijms-20-03304]\] ([Figure 2](#ijms-20-03304-f002){ref-type="fig"}). Consequently, its impairment leads to a lack of complex gangliosides and accumulation of GM3 and GD3. Twelve pathogenic variants of the gene have been reported so far in 12 families, involving 38 individuals, all showing a form of complex HSP previously referred to as HSP26 \[[@B90-ijms-20-03304],[@B91-ijms-20-03304],[@B92-ijms-20-03304]\]. The syndrome is characterized by late onset of motor impairment of the legs accompanied by mild to moderate cognitive impairment, sometimes associated with psychiatric illness and/or non-neurological symptoms such as pes cavus or hypogonadism in males ([Table 3](#ijms-20-03304-t003){ref-type="table"}). Very recently \[[@B93-ijms-20-03304]\], it has been reported that nine out of 11 tested mutations lead to a complete loss of enzyme activity, while two variants (R300C and R228\*) maintain a small but detectable residual activity in vitro. Three variants appeared not detectable by western blot, while the other eight were found to be correctly localized to the Golgi apparatus by confocal microscopy, suggesting that the loss of function is the main pathogenic event. This hypothesis is also supported by the evidence that b4galnt1 KO mice present a similar phenotype \[[@B94-ijms-20-03304]\], although in some but not all cases \[[@B95-ijms-20-03304]\]. However, HSP is due to the defect of a plethora of different genes \[[@B34-ijms-20-03304]\]. Two of them directly involve sphingolipid metabolism in addition to *B4GALNT1*: *GBA2*, responsible for HSP46 \[[@B28-ijms-20-03304]\], and *FA2H*, involved in HSP35 \[[@B96-ijms-20-03304]\] and coding for fatty acid 2-hydroxylase \[[@B97-ijms-20-03304]\]. Interestingly, HSP11 is due to the loss of function of spatacsin, a product of the *SPG11* gene, which is involved in lysosome membrane recycling. In the spg11 KO mouse model \[[@B98-ijms-20-03304]\], loss of spatacsin impairs ganglioside clearance from the lysosome and determines the accumulation of autophagy markers. In addition, neurodegeneration was stimulated by the accumulation of gangliosides in cultured neurons and was prevented by miglustat. The same authors were also able to reduce motor impairment by inhibiting ganglioside biosynthesis in the HSP11 zebrafish model.

4.2. GM3 Synthase Deficiency (ST3GAL5-CDG) {#sec4dot2-ijms-20-03304}
------------------------------------------

ST3GAL5 displays unique GM3 synthase activity, being responsible for the biosynthesis of ganglio-series gangliosides of the a-, b-, and c-series, with the exception of 0-series gangliosides, such as GM1b and GD1α \[[@B99-ijms-20-03304]\] ([Figure 2](#ijms-20-03304-f002){ref-type="fig"}). Five different pathogenic mutations have been reported so far, all causing a very severe syndrome characterized by normal pregnancy and delivery but early onset of neurological symptoms including drug-resistant epilepsy, failure to thrive, and impaired hearing and vision. Growth delay and progressive regression occur, giving rise to deafness, blindness, and general motor and cognitive impairment \[[@B25-ijms-20-03304],[@B100-ijms-20-03304]\]. While the original description of a few families suggested a potential different degree of pathogenicity between mutations \[[@B101-ijms-20-03304],[@B102-ijms-20-03304],[@B103-ijms-20-03304]\], a recent survey of several cases affected by the same R288\* non-sense mutation indicated the opposite \[[@B104-ijms-20-03304]\]. Some of these patients lack clinical seizures or were initially able to crawl, as originally reported only for two siblings carrying the compound C195S/G201A mutations \[[@B103-ijms-20-03304]\]. Accordingly, we have recently shown that all reported mutations abolish any detectable enzyme activity, without differences between the single mutations \[[@B100-ijms-20-03304]\]. Moreover, we also found a normal localization of the variant ST3GAL5s. Altogether, this data is in agreement with the current hypothesis that the total absence of gangliosides is responsible for the general lack of neuron homeostasis, leading to inflammation and, consequently, loss of several functions \[[@B105-ijms-20-03304]\]. However, many patients present mildly elevated blood lactate and their cells have an impaired respiratory chain function \[[@B25-ijms-20-03304],[@B100-ijms-20-03304]\]. In this context, the hypothesis that impaired autophagy and, in particular, mitophagy may be involved in the disease pathogenesis should be kept in mind. The enormous distance between the devastating human syndrome and the very mild KO mouse model \[[@B106-ijms-20-03304],[@B107-ijms-20-03304]\] corroborates such a suggestion.

4.3. ST3GAL3-CDG, Non-Syndromic Intellectual Disability and West Syndrome {#sec4dot3-ijms-20-03304}
-------------------------------------------------------------------------

ST3GAL3 is considered the enzyme responsible for the α2,3 sialylation of galactose preferentially β1,3 linked to GlcNAc in several glycoconjugates, including glycoproteins carrying both N- and O- glycans and GSLs of the lacto-series \[[@B108-ijms-20-03304],[@B109-ijms-20-03304]\]. Data obtained in vitro with the mouse enzyme suggested a strong preference for the Galβ1,3GlcNAc acceptor sequence \[[@B110-ijms-20-03304]\], ruling out the ability to use the Galβ1,3GalNAc sequence, including ganglio-series gangliosides. Conversely, double st3gal2/st3gal3 KO mice exhibited substantial loss of GD1a and GT1b gangliosides in their brain, not found in single st3gal2 KO animals, suggesting the ability of the enzyme to use the Galβ1,3GalNAc sequence of GSLs in vivo \[[@B111-ijms-20-03304]\]. Detailed data are not available for the human enzyme, which is considered involved in the α2,3 sialylation of the Galβ1,3GlcNAc sequence necessary for constructing the tetrasaccharide epitope of the CA19.9 antigen \[[@B112-ijms-20-03304]\], an adhesion molecule potentially involved in cancer \[[@B113-ijms-20-03304],[@B114-ijms-20-03304]\].

Two pathogenic variants of ST3GAL3 were found in adult members of two families reported to suffer from non-syndromic autosomal recessive intellectual disability \[[@B115-ijms-20-03304]\]. The A13N variant appeared to be associated with preserved enzymatic activity in vitro and even only partial retention of the protein in the ER.

Conversely, the other mutation, N370T, was found to determine total loss of enzymatic activity together with substantial retention in the ER. Further, a third mutation (A320P) was reported in four infants from a consanguineous family that were diagnosed with West syndrome, evolved to Lennox--Gestaut syndrome \[[@B35-ijms-20-03304]\], which are age-dependent epileptic encephalopathic syndromes defined by a specific electroencephalography pattern and associated with developmental arrest or regression. Such a mutation provided a complete loss of enzymatic activity and impaired protein localization \[[@B116-ijms-20-03304]\].

Recently, neurons differentiated from iPSc cells obtained from fibroblasts carrying the A320P mutation \[[@B116-ijms-20-03304]\] were studied in order to find the glycoproteins lacking sialyl-α2,3 residues, as assessed by *Maackia amurensis* labeling. A defect in a single 80-kDa glycoprotein was detected in differentiated cortical neurons, together with altered adhesion properties. In the st3gal3 KO mouse model of the disease, the animals lack neurologic symptoms, presenting only mild immunologic anomalies \[[@B117-ijms-20-03304],[@B118-ijms-20-03304]\]. In this case, retention in the ER of the variants suggests that they could be misfolded, irrespective of the catalytic activity maintained, and this would be compatible with a pathogenic role of altered proteostasis, irrespective of the lack of sialylation, on either glycoproteins or glycosphingolipids.

5. Conclusions {#sec5-ijms-20-03304}
==============

Recent studies on the GD/PD relationship demonstrate that GBA variants predispose individuals to PD through molecular mechanisms that have the potential to operate in other disorders affecting sphingolipid metabolism, leading in turn to neurodegeneration.

One such mechanism depends on the amounts of individual molecules accumulated. It has been well proven in the case of the inflammatory role played by GlcCer through the activation of complement in the tissues affected by type 1 GD \[[@B45-ijms-20-03304]\]. This is also potentially relevant in conditions where gene mutations predispose individuals to the accumulation of non-physiologic by-products, such as lysosphingolipids in several diseases. ([Table 1](#ijms-20-03304-t001){ref-type="table"}), deoxysphingolipids in hereditary sensory neuropathy type 1, and Δ14-cis sphingolipids in defective desaturase activity ([Table 2](#ijms-20-03304-t002){ref-type="table"}). Similarly, a direct pathogenic effect is possibly due to the lack of specific products in the diseases affecting biosynthetic enzymes, as typically seen in ST3GAL5 deficiency.

Another relevant mechanism suggested by the GBA/PD relationship involves the traffic of vesicles towards lysosomes, affecting autophagy. The peculiar role of autophagy in the survival of neurons is well known, as well as the pathogenic role of its impairment in neurodegeneration \[[@B119-ijms-20-03304]\]. In PD, α-synuclein accumulation appears strongly dependent on autophagy, as detailed in the section above. Sphingolipid metabolism strongly interplays with neuronal autophagy, with particular relevance of gangliosides, ceramide, SM, S1P, and GlcCer. Autophagy is impaired by increased GlcCer and SM levels, as determined by GBA and sphingomyelinase SMPD1 deficits, but stimulated by increased ceramide levels (reviewed in \[[@B120-ijms-20-03304]\]) or impaired by reduced levels \[[@B59-ijms-20-03304]\]. Some HSPs are due to impaired sphingolipid metabolism, others to defective mitochondrial proteins, and others to gene mutations that code proteins involved in organelle trafficking and shape \[[@B34-ijms-20-03304]\]. One of the latter, spastin, is considered particularly relevant in the disease pathogenesis suggesting that toxic gain-of-function mechanisms operate in a context of a nervous system made vulnerable by haploinsufficiency \[[@B121-ijms-20-03304]\]. A reasonable hypothesis is that any imbalance between the amounts of individual sphingolipids may impair endocytic trafficking, affecting cargo load or autophagy directly, as proven for GBA variants. In this regard, it is important to note that some models revealed specific impairment of mitophagy in PD \[[@B64-ijms-20-03304]\]. In ST3GAL5-CDG, the lack of ganglio-series gangliosides is probably accompanied by the accumulation of globosides, and mitochondrial defects are present, sometimes reported to misdirect the diagnosis \[[@B122-ijms-20-03304]\], although brain mitochondria lack gangliosides \[[@B123-ijms-20-03304]\]; we speculate that impaired mitophagy may occur in the disease as suggested for lysosomal storage diseases \[[@B124-ijms-20-03304]\].

Finally, GBA variants affect cell homeostasis through altered proteostasis due to ER stress or other consequences of protein misfolding \[[@B39-ijms-20-03304],[@B48-ijms-20-03304],[@B54-ijms-20-03304]\]. In ST3GAL3-CDG, protein variants were reported to be improperly localized and partially retained in the ER.

A growing number of pharmacologic inhibitors of sphingolipid metabolism are available and studied as drugs potentially suitable in human diseases \[[@B125-ijms-20-03304]\]. Once those able to cross the blood--brain barrier are selected, it will be possible in the future to use them to target the pathogenic mechanisms of some neurodegenerative disorders, possibly in association with the substances potentially able to affect lysosomal function, autophagy, and proteostasis \[[@B68-ijms-20-03304],[@B69-ijms-20-03304],[@B126-ijms-20-03304]\].
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![Biosynthesis and degradation of ceramide. SPTLC, serine palmitoyl transferase; KDSR, 3-keto-dihydro-sphingosine reductase; CERS, dihydroceramide synthase; DEGS, dihydroceramide desaturase; ASAH, acid ceramidase; ACER, alkaline ceramidase; SPHK, sphingosine kinase; SGPL1, sphingosine lyase. For simplicity, only stearic acid is depicted as the acyl chain of ceramides, but longer fatty acids can be added by different CERSs.](ijms-20-03304-g001){#ijms-20-03304-f001}

![Biosynthesis and degradation of complex glycosphingolipids. Monosaccharides are depicted according to the current representation: Glc, glucose; Gal, galactose; GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine; Sia, sialic acid. Enzyme symbols are according to the HUGO nomenclature (see [Table 2](#ijms-20-03304-t002){ref-type="table"}; [Table 3](#ijms-20-03304-t003){ref-type="table"} for enzyme details). UGT8, GalCer synthase; GALC, galactocerebrosidase; SGMS, sphingomyelin synthase; SMPD, sphingomyelinase; UGCG, GlcCer synthase; GBA, glucocerebrosidase; B4GALT, β1,4-galactosyltransferase; GLB1, β-galactosidase; A4GALT, α1,4-galactosyltransferase; GLA, α-galactosidase; B3GALT, β1,3-GalNActransferase; Hex, hexosaminidase; B3GNT, β1,3-GlcNAc transferase; B3GALT, β1,3-galactosyltransferase; ST3GAL, galactoside-α2,3-sialyltransferase; NEU, neuraminidase (sialidase). Lc3, lactotriaosylceramide GlcNAcβ1,3Galβ1,4GlcCer; Lc4, lactotetraosylceramide; LM1, sialyllactotetraosylceramide, Siaα2,3Galβ1,3GlcNAcβ1,3Galβ1,4GlcCer; Gb3, globotriaosylceramide Galα1,3Galβ1,4GlcCer; Gb4, globotetraosylceramide GalNAcβ1,3Galα1,3Galβ1,4GlcCer.](ijms-20-03304-g002){#ijms-20-03304-f002}

![Structure of lysosphingolipids and related compounds. Lysosphingolipds are complex sphingolipids deacylated by the action of acid ceramidase on the corresponding compounds accumulated because of an inborn error of metabolism. Sph, sphingosine. For simplicity, only stearic acid is depicted as the acyl chain, but longer fatty acids are also frequently present.](ijms-20-03304-g003){#ijms-20-03304-f003}

ijms-20-03304-t001_Table 1

###### 

Enzymes involved in sphingolipid degradation and recycling.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Enzyme                      Hugo Symbol                        Subcellular Site                                     Disease                                                                                                                                                                                       Main Clinical Features                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Biochemical Features                                                                                                                                                                                                                                                                                                Ref
  --------------------------- ---------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  Acid ceramidase             ASAH1                              Lysosome                                             Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy                                                                                                                Typical spectrum disease varying from the classic triad of subcutaneous nodules, joint contractures, and hoarse voice to moderate or severe forms involving hematopoietic, gastrointestinal, respiratory, and neurologic symptoms, including seizures; developmental delay and death in the early childhood.                                                                                                                                                                                                     The same Y137C mutation provided very mild phenotype in a patient and severe neurologic phenotype in another. Two SNPs are associated with schizophrenia. Residual activity \>5% is associated with survival. Candidate risk factor for Parkinson´s disease (PD).                                                   \[[@B29-ijms-20-03304],[@B73-ijms-20-03304],[@B127-ijms-20-03304]\]

  Neutral ceramidase          ASAH2                              Plasma membrane                                      None reported                                                                                                                                                                                 Main expression in the small intestine and colon, probable role in digestion.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \[[@B128-ijms-20-03304]\]

  Alkaline ceramidases        ACER1                              Endoplasmic reticulum (ER)                           Main expression in the skin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   \[[@B129-ijms-20-03304]\]                                                                                                                                                                                                                                                                                           

  ACER2                       Golgi apparatus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  ACER3                       ER and Golgi apparatus             Progressive leukodystrophy                           Developmental regression at 6--13 months, starting with peripheral neuropathy and leading to severe dysmorphic facial feature and psychomotor impairment, requiring mechanical ventilation.   Plasma accumulation of ceramides, dihydroceramides, glucosylceramide (GlcCer), and lactosylceramide (LacCer). Increased blood lactate levels.                                                                                                                                                                                                                                                                                                                                                                    \[[@B30-ijms-20-03304]\]                                                                                                                                                                                                                                                                                            

  Sphingosine kinases         SPHK1                              Plasma membrane (main)                               None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \[[@B130-ijms-20-03304]\]

  SPHK2                       ER (main)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Sphingosine lyase           SGPL1                              ER                                                   Syndromic steroid-resistant nephrotic syndrome                                                                                                                                                Steroid-resistant nephrotic syndrome with facultative ichthyosis, adrenal insufficiency, immunodeficiency, and neurological defects.                                                                                                                                                                                                                                                                                                                                                                             Reduced activity and protein mislocalization are frequent between mutations. Ceramides are elevated in the conditioned culture medium of patient fibroblasts.                                                                                                                                                       \[[@B131-ijms-20-03304]\]

  Galacto-cerebrosidase       GALC                               Lysosome                                             Krabbe disease                                                                                                                                                                                Infantile onset (within 6 months). Increased irritability, spasticity, developmental delay along with unexplained fever, blindness, and deafness. Severe motor and mental deterioration.                                                                                                                                                                                                                                                                                                                         Poor genotype--phenotype relationship. Galactosyl-sphingosine (psychosine) accumulates, affecting endolysosomal transport and pH. Aggregated forms of α-synuclein reported.                                                                                                                                         \[[@B37-ijms-20-03304],[@B49-ijms-20-03304],[@B79-ijms-20-03304],[@B91-ijms-20-03304]\]

  Gluco-cerebrosidases        GBA                                Lysosome                                             Gaucher disease                                                                                                                                                                               Type 1 disease classically includes inflammatory signs in visceral organs that appear in adulthood; types 2 and 3 are instead neuronopathic, with early onset and progression at different rates. Recently proposed to be a spectrum disease. Main genetic risk factor for PD even in heterozygous carriers (see details in the text).                                                                                                                                                                           Poor genotype--phenotype relationship. GlcCer and glucosylsphingosine accumulate, affecting vesicle traffic and autophagy including mitophagy, which are also impaired by altered proteostasis. Strong evidence that glucocerebrosidase (GBA) variants affect α-synuclein accumulation (see details in the text).   \[[@B27-ijms-20-03304],[@B33-ijms-20-03304],[@B50-ijms-20-03304],[@B54-ijms-20-03304],[@B57-ijms-20-03304]\]

  GBA2                        Microsomes                         HSP46/Cerebellar ataxia with late-onset spasticity   Early onset of motor impairment with mental retardation, cataract, and hypogonadism in males. MRI: cerebellar and corpus callosum atrophy.                                                    Loss of enzymatic activity in almost all known mutations. Inhibition of activity in fibroblasts from Niemann--Pick patients restores endolysosomal pH.                                                                                                                                                                                                                                                                                                                                                           \[[@B28-ijms-20-03304],[@B44-ijms-20-03304],[@B72-ijms-20-03304]\]                                                                                                                                                                                                                                                  

  β-galactosidase             GLB1                               Lysosome                                             GM1 gangliosidosis                                                                                                                                                                            Infantile form: early onset and rapid progressive psychomotor deterioration, skeletal abnormalities, visceromegaly, and death. Juvenile and adult phenotypes characterized by slowly progressive neurological degeneration and mild skeletal changes.                                                                                                                                                                                                                                                            Poor genotype--phenotype correlation. GM1, LacCer, and lactosylsphingosine accumulate causing impairment of endolysosomal transport and pH, autophagy, and mitochondrial function). ER stress detected.                                                                                                             \[[@B81-ijms-20-03304],[@B99-ijms-20-03304]\]

  Hexosaminidase A            HEXA                               Lysosome                                             Tay--Sachs disease                                                                                                                                                                            Infantile form: early onset of neurodevelopmental dysfunctions, hypotonia and eye movement abnormalities. Progression includes dysphagia, seizures, macrocephaly, and death until age 3.5 years.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \[[@B99-ijms-20-03304]\]
                                                                                                                                                                                                                                                                                                                    Juvenile onset includes ataxia, dysarthria, dysphagia, progressive hypotonia, seizures, and death until 15 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Hexosaminidase B            HEXB                               Lysosome                                             Sandhoff disease                                                                                                                                                                              Juvenile onset form: reduced attention, weakness, hypotonia, and progressive psychomotor impairment.\                                                                                                                                                                                                                                                                                                                                                                                                            GM2, asialo-GM2, and globoside accumulate. Deposits of α-synuclein reported.                                                                                                                                                                                                                                        \[[@B49-ijms-20-03304],[@B99-ijms-20-03304]\]
                                                                                                                                                                                                                                                                                                                    Adult-onset form: milder phenotype due to residual enzymatic activity. Muscle weakness and motor symptoms.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  GM2 activator               GM2A                               Lysosome                                             GM2 gangliosidosis                                                                                                                                                                            Similar to Tay--Sachs disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \[[@B99-ijms-20-03304]\]

  α-galactosidase             GLA                                Lysosome                                             Fabry disease                                                                                                                                                                                 X-linked recessive, phenotypes from healthy to severe in women, severe to fatal in men. Various organs potentially involved, including peripheral and central nervous system. Cardiovascular involvement is frequent and at high risk for stroke and arrhythmias.                                                                                                                                                                                                                                                Globotriaosylceramide and globotriaosylsphingosine accumulate. Activity of respiratory chain enzymes reduced, protein trafficking and sorting altered, autophagy-lysosome pathway dysregulated. Impaired α-synuclein degradation.                                                                                   \[[@B38-ijms-20-03304],[@B76-ijms-20-03304],[@B132-ijms-20-03304]\]

  Acid sphingomyelinase       SMPD1                              Lysosome and secretory                               Niemann--Pick disease types A and B                                                                                                                                                           The gene is paternally imprinted.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Good genotype-phenotype correlation. Sphingomyelin and lysosphingomyelin (sphingosine-phosphocoline) accumulate. Increased levels of cholesterol, GlcCer, LacCer, and gangliosides. Decreased activity levels led to α-synuclein accumulation.                                                                      \[[@B22-ijms-20-03304],[@B36-ijms-20-03304]\]
                                                                                                                                                                                                                                                                                                                    Type A: acute, early onset with failure to thrive and hepatosplenomegaly. Rapid and progressive neurodegenerative course, hypothonia and death until age of 3 years. Cherry-red spot in the macula. Type B: chronic, no neurologic signs. Hepato-splenomegaly and signs of liver failure. Impaired pulmonary function. High levels of serum triglycerides and LDL-cholesterol, low levels of HDL-cholesterol. Reddish brown or cherry red spot in the macula. SMPD1 variants are confirmed risk factor for PD.                                                                                                                                                                                                                                                                                                                       

  Neutral sphingomyelinases   SMPD2                              Plasma membrane                                      None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \[[@B22-ijms-20-03304]\]

  SMPD3                       ER, Golgi apparatus, and nucleus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  SMPD4                       ER and Golgi apparatus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  SMPD5                       Mitochondria and ER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ijms-20-03304-t002_Table 2

###### 

Endoplasmic reticulum resident enzymes involved in the initial biosynthesis of sphingolipids.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Enzyme                                 Hugo Symbol                      Disease                                                            Inheritance                                                                                                                                                              Main Clinical Features                                                                                                                                                                                                                      Biochemical Features                                                                                                                                               Ref.
  -------------------------------------- -------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------
  Serine palmitoyl transferases          SPTLC1                           Hereditary sensory neuropathy (Type 1)                             Autosomal dominant                                                                                                                                                       Onset of sensory impairment spanning the second to fifth decades, frequent motor impairment and burning pain episodes; distal to proximal progression. Mutations of either one or two subunits determine identical clinical phenotypes.     Alanine and glycine used instead of serine producing deoxysphinganine and deoxyceramide, which have mitochondrial toxicity in vitro.                               \[[@B9-ijms-20-03304],[@B10-ijms-20-03304]\]

  SPTLC2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  SPTLC3                                 None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  3-keto-dihydro-sphingosine reductase   KDSR                             Erythrokeratoderma or ichtyosis with anemia and thrombocytopenia   Autosomal recessive                                                                                                                                                      No neurologic signs. Heterogeneous skin and hematologic symptoms; spontaneous remission with age in some cases.                                                                                                                             Retinoic acid therapy effective, probably stimulating salvage pathway from sphingosine.                                                                            \[[@B11-ijms-20-03304],[@B12-ijms-20-03304],[@B13-ijms-20-03304]\]

  Dihydro-ceramide synthases             CERS1                            Myoclonus epilepsy                                                 Autosomal recessive                                                                                                                                                      Ataxia at the age of one year, delay in development, generalized tonic--clonic seizures, action myoclonus with onset between 6 and 16 years of age. Cognitive deterioration up to dementia.Magnetic resonance imaging: brainstem atrophy.                                                                                                                                                                      \[[@B14-ijms-20-03304],[@B15-ijms-20-03304]\]

  CERS2                                  Progressive myoclonus epilepsy   27 kb heterozygous deletion                                        Tonic--clonic seizures prevented by valproic acid, learning disability, progressive myoclonic epilepsy, moderate intellectually disability with dysarthria and ataxia.                                                                                                                                                                                                                                               \[[@B17-ijms-20-03304]\]                                                                                                                                           

  CERS3                                  Congenital ichthyosis            Autosomal recessive                                                No neurologic signs. Congenital ichthyosis characterized by collodion membranes at birth, generalized scaling of the skin, and mild erythroderma.                        Specific loss of ceramides with acyl chains from C26 up to C34 in keratinocytes.                                                                                                                                                            \[[@B16-ijms-20-03304]\]                                                                                                                                           

  CERS4                                  None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            \[[@B18-ijms-20-03304]\]                                                                                                                                           

  CERS5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  CERS6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Dihydro-ceramide desaturases           DEGS1                            Hypomyelinating Leukodystrophy                                     Autosomal recessive                                                                                                                                                      Onset at 0.5--24 months. Failure to thrive, developmental delay, epilepsy, neurogenic muscular atrophy, severe motor arrest, microcephaly, dystonia and severe spasticity.\                                                                 Presence of Δ14-cis sphingolipids; inhibition of CERS ameliorates phenotype in zebrafish model, and reactive oxygen species (ROS) levels in patient fibroblasts.   \[[@B20-ijms-20-03304],[@B21-ijms-20-03304]\]
                                                                                                                                                                                                                                                                                                                      MRI: hypomyelination, thin white matter, progressive thalamic and cerebellar atrophy.                                                                                                                                                                                                                                                                                                                          

  DEGS2                                  None reported                                                                                       Relevant in stratum corneum.                                                                                                                                             Involved in the metabolism of sphingolipid containing 4-hydroxysphingosine (phytosphingosine).                                                                                                                                              \[[@B19-ijms-20-03304]\]                                                                                                                                           

  SM synthase related protein            SAMD8                            None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Involved in the synthesis of ceramide phosphoethanolamine.                                                                                                         \[[@B22-ijms-20-03304]\]

  GalCer synthase                        UGT8                             None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ijms-20-03304-t003_Table 3

###### 

Golgi apparatus resident enzyme involved in the biosynthesis of complex sphingolipids. Note that sphingomyelin synthase SGMS2 resides in the plasma membrane.

  Enzyme                                                  Hugo Symbol                            Disease                                                                   Inheritance                                                                                                                                                                              Main Clinical Features                                                                                                                                                                                    Biochemical Features                                                             Ref.
  ------------------------------------------------------- -------------------------------------- ------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  Sphingomyelin synthases                                 SGMS1                                  None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \[[@B22-ijms-20-03304]\]
  SGMS2 (plasma membrane resident)                        Osteoporosis with skeletal dysplasia   Autosomal dominant                                                        Minor neurologic signs detectable in some cases. Childhood onset osteoporosis with or without cranial sclerosis, neonatal fractures, short stature, and spondylometaphyseal dysplasia.   Variants are frequently mislocalized or retained in the ER; catalytic activity maintained by some variants.                                                                                               \[[@B23-ijms-20-03304]\]                                                         
  Glucosylceramide synthase                               UGCG                                   Congenital ichthyosis                                                     Autosomal recessive                                                                                                                                                                      Normal growth parameters at birth, but covered with a collodion membrane; death at age 2 weeks because of severe hypernatremic anuric renal failure.                                                      Phenotype similar to that of the keratinocyte-conditional KO mouse.              \[[@B24-ijms-20-03304]\]
  UDP-Gal: GlcCer β1,4-galactosyltransferase              B4GALT6                                None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                Synthesizes lactosylceramide.                                                    
  UDP-Gal: lactosylceramideα-1,4-galactosyl-transferase   A4GALT                                                                                                                                                                                                                                                                                                    Synthesizes globotriosyl ceramide.                                                                                                                                                                                                                                                         
  UDP-GlcNAc: lactosylceramide β-1,4-GlcNAc transferase   B3GNT5                                                                                                                                                                                                                                                                                                    Synthesizes lacto-N-triosyl ceramide.                                                                                                                                                                                                                                                      
  GM3 synthase                                            ST3GAL5                                ST3GAL5-CDG                                                               Autosomal recessive                                                                                                                                                                      Normal at birth, early onset severe neurological signs. Failure to thrive, regression, severe hearing, visual, motor, and cognitive impairment (see details in the text).                                 Mitochondrial defects in patients. Globosides accumulate in human fibroblasts.   \[[@B25-ijms-20-03304],[@B100-ijms-20-03304],[@B101-ijms-20-03304],[@B102-ijms-20-03304],[@B103-ijms-20-03304],[@B104-ijms-20-03304]\]
  GM2/GD2/GA2 synthase                                    B4GALNT1                               Hereditary spastic paraplegia 26 (B4GALNT1-CDG)                           Autosomal recessive                                                                                                                                                                      Late onset motor impairment of the legs accompanied by mild to moderate cognitive impairment, sometimes associated with psychiatric illness and/or non-neurological symptoms (see details in the text).   GM3 and GD3 accumulate in vivo and in vitro models.                              \[[@B90-ijms-20-03304],[@B91-ijms-20-03304],[@B92-ijms-20-03304]\]
  UDP-Gal: GM2/GD2/GA2 β1,3-galactosyltransferase         B3GALT4                                None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                Synthesizes gangliosides GM1, GD1a, and GD1b.                                    
  CMP-Sial: GlcNAcβ1,3(4) sialyltransferase               ST3GAL3                                Non syndromic autosomal recessive intellectual disability/West syndrome   Autosomal recessive                                                                                                                                                                      Only intellectual disability reported when diagnosed in adults, West syndrome when diagnosed in early childhood (see details in the text).                                                                ER retention frequent in variants, enzyme activity maintained in one variant.    \[[@B35-ijms-20-03304],[@B115-ijms-20-03304],[@B116-ijms-20-03304]\]
